Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
APRESOLINE / hydralazine
Generic name / active ingredient
hydralazine hydrochloride immediate-release tablets
Dosage-form class
Hydralazine hydrochloride immediate-release oral tablets. Products outside this oral-tablet identity include the 20 mg/mL injection, the BIDIL isosorbide dinitrate/hydralazine hydrochloride fixed combination and other antihypertensives. Historical originator APRESOLINE and current generic tablets also remain separate. A shared ingredient, purpose or milligram figure does not establish conversion, tablet count, frequency, titration, splitting or substitution.
Route
Oral
Record reviewed
2026-09-02

Copy from the pack in hand

Source-linked reading points

  • Dizziness, darkening vision on standing, marked weakness, palpitations or syncope may accompany low blood pressure. Older adults, people at higher fall risk or those using other antihypertensives require timely review of the complete medicine list. Severe syncope, injury or altered awareness needs local emergency care.
  • Hydralazine can cause myocardial stimulation, tachycardia and angina; the label links it to myocardial ischaemia and notes implication in myocardial infarction. New or worsening chest pain, marked breathlessness, cold sweat or radiating pain must not wait for a webpage and requires local emergency care.
  • Longer treatment can cause a syndrome resembling systemic lupus erythematosus, including glomerulonephritis. Joint pain, fever, chest pain, marked malaise, rash or urinary/kidney changes need treating-team review. Periodic complete blood count and antinuclear antibody testing described by the label belongs to the responsible team; the site does not order tests.
  • Numbness, tingling or burning can suggest peripheral neuritis. The label also lists reduced haemoglobin/red cells, leucopenia, agranulocytosis or purpura. Progressive neurological symptoms, fever/sore throat, unusual bleeding or bruising needs prompt medical review.

Reviewed presentation examples — compare every field

  • 10 mg hydralazine hydrochloride per tablet; 100-tablet bottleNDC 64380-733-06
  • 10 mg hydralazine hydrochloride per tablet; 500-tablet bottleNDC 64380-733-07
  • 10 mg hydralazine hydrochloride per tablet; 1000-tablet bottleNDC 64380-733-08
  • 25 mg hydralazine hydrochloride per tablet; 100-tablet bottleNDC 64380-734-06
  • 25 mg hydralazine hydrochloride per tablet; 500-tablet bottleNDC 64380-734-07
  • 25 mg hydralazine hydrochloride per tablet; 1000-tablet bottleNDC 64380-734-08
  • 50 mg hydralazine hydrochloride per tablet; 100-tablet bottleNDC 64380-735-06
  • 50 mg hydralazine hydrochloride per tablet; 500-tablet bottleNDC 64380-735-07

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-09-02
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image